Home > > > > > Report Detail

Pyelonephritis - Pipeline Review, H2 2019

Publisher Name :
Date: 25-Nov-2019
No. of pages: 122
Inquire Before Buying

Pyelonephritis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H2 2019, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 6, 1 and 2 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Pyelonephritis - Pipeline Review, H2 2019

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pyelonephritis - Overview
Pyelonephritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pyelonephritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pyelonephritis - Companies Involved in Therapeutics Development
Achaogen Inc
Allecra Therapeutics GmbH
AlloVir Inc
Entasis Therapeutics Inc
Iterum Therapeutics Plc
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
XuanZhu Pharma Co Ltd
Pyelonephritis - Drug Profiles
(AAI-101 + cefepime) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + VNRX-5133) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(meropenem + vaborbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALVR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benapenem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceforanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfomycin disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nacubactam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulopenem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tebipenem pivoxil hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pyelonephritis - Dormant Projects
Pyelonephritis - Discontinued Products
Pyelonephritis - Product Development Milestones
Featured News & Press Releases
Sep 03, 2019: Allecra Therapeutics to present data at ASM/ESCMID 2019 Conference on drug development to meet the challenge of antimicrobial resistance
Jul 29, 2019: Merck receives positive EU CHMP opinion for ZERBAXA 3g dose (ceftolozane and tazobactam) for the treatment of adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
Apr 15, 2019: Paratek Pharmaceuticals broadens clinical profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations
Apr 10, 2019: Entasis Therapeutics announces presentations on ETX2514SUL at ECCMID 2019
Mar 29, 2019: Spero Therapeutics receives FDA fast track designation for SPR994 for the treatment of complicated urinary tract infections and acute pyelonephritis
Feb 21, 2019: Achaogen announces ZEMDRI (plazomicin) pivotal phase 3 study results published in the New England Journal of Medicine
Feb 14, 2019: Achaogen submits response to ASPR/BARDA request for information (RFI) for antimicrobial resistance project BioShield
Dec 11, 2018: The Menarini Group announces Meropenem/vaborbactam European marketing authorization
Nov 27, 2018: Paratek Pharmaceuticals doses first patient in phase 2 clinical trial of Omadacycline in acute pyelonephritis, a common subset of complicated urinary tract infections
Oct 17, 2018: Achaogen submits marketing authorization application to the European Medicines Agency for Plazomicin
Oct 03, 2018: Entasis Therapeutics to Present on ETX2514SUL at IDWeek 2018
Sep 19, 2018: Achaogen announces multiple Plazomicin presentations at IDWeek 2018
Sep 04, 2018: Achaogen highlights multiple Plazomicin presentations at ESCMID/ASM 2018 Conference
Aug 14, 2018: Entasis Therapeutics announces positive topline results from phase 2 trial of ETX2514SUL in patients with complicated urinary tract infections including acute pyelonephritis
Aug 03, 2018: CMS grants new technology add-on payment to ZEMDRI (plazomicin)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Pyelonephritis, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Pyelonephritis - Pipeline by Achaogen Inc, H2 2019
Table 9: Pyelonephritis - Pipeline by Allecra Therapeutics GmbH, H2 2019
Table 10: Pyelonephritis - Pipeline by AlloVir Inc, H2 2019
Table 11: Pyelonephritis - Pipeline by Entasis Therapeutics Inc, H2 2019
Table 12: Pyelonephritis - Pipeline by Iterum Therapeutics Plc, H2 2019
Table 13: Pyelonephritis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, H2 2019
Table 14: Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, H2 2019
Table 15: Pyelonephritis - Pipeline by Melinta Therapeutics Inc, H2 2019
Table 16: Pyelonephritis - Pipeline by Merck & Co Inc, H2 2019
Table 17: Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2019
Table 18: Pyelonephritis - Pipeline by Nabriva Therapeutics Plc, H2 2019
Table 19: Pyelonephritis - Pipeline by Paratek Pharmaceuticals Inc, H2 2019
Table 20: Pyelonephritis - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2019
Table 21: Pyelonephritis - Pipeline by Wockhardt Ltd, H2 2019
Table 22: Pyelonephritis - Pipeline by XuanZhu Pharma Co Ltd, H2 2019
Table 23: Pyelonephritis - Dormant Projects, H2 2019
Table 24: Pyelonephritis - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Pyelonephritis, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019
  • Global Cephalosporin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 109
    Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from The fungus Acremonium, which was previously known as "Cephalosporium". The global Cephalosporin market was valued at US$ 1380.7 million in 2023 and is anticipated to reach US$ 1346.9 million by 2030, witnessing a CAGR of -0.3% during The forecast period 2024-2030. Market competition is intense. Qilu Antibiotics, Nectar Lifes......
  • Global Polymixin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 120
    According to our LPI (LP Information) latest study, the global Polymixin market size was valued at US$ 229.9 million in 2023. With growing demand in downstream market, the Polymixin is forecast to a readjusted size of US$ 291 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Polymixin market. Polymixin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and sup......
  • Global Sepsis Partnering Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The Sepsis Partnering market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sepsis Partnering market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape......
  • Global Cephalosporin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 156
    According to our LPI (LP Information) latest study, the global Cephalosporin market size was valued at US$ 1350.7 million in 2023. With growing demand in downstream market, the Cephalosporin is forecast to a readjusted size of US$ 1319.6 million by 2030 with a CAGR of -0.3% during review period. The research report highlights the growth potential of the global Cephalosporin market. Cephalosporin are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Amoxicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 127
    According to our LPI (LP Information) latest study, the global Amoxicillin market size was valued at US$ 4512.7 million in 2023. With growing demand in downstream market, the Amoxicillin is forecast to a readjusted size of US$ 5711.7 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Amoxicillin market. Amoxicillin are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Metronidazole Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 136
    According to our LPI (LP Information) latest study, the global Metronidazole market size was valued at US$ 110.5 million in 2023. With growing demand in downstream market, the Metronidazole is forecast to a readjusted size of US$ 106.6 million by 2030 with a CAGR of -0.5% during review period. The research report highlights the growth potential of the global Metronidazole market. Metronidazole are expected to show stable growth in the future market. However, product differentiation, redu......
  • Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Drugs for Herpes Labialis (Oral Herpes) market size was valued at US$ 2404.5 million in 2023. With growing demand in downstream market, the Drugs for Herpes Labialis (Oral Herpes) is forecast to a readjusted size of US$ 3402.2 million by 2030 with a CAGR of 5.1% during review period. The research report highlights the growth potential of the global Drugs for Herpes Labialis (Oral Herpes) market. Drugs for Herpes Labialis (Ora......
  • Global Ampicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Ampicillin market size was valued at US$ 161.6 million in 2023. With growing demand in downstream market, the Ampicillin is forecast to a readjusted size of US$ 194.7 million by 2030 with a CAGR of 2.7% during review period. The research report highlights the growth potential of the global Ampicillin market. Ampicillin are expected to show stable growth in the future market. However, product differentiation, reducing costs, a......
  • Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Acinetobacter Infections Treatment market size was valued at US$ million in 2023. With growing demand in downstream market, the Acinetobacter Infections Treatment is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Acinetobacter Infections Treatment market. Acinetobacter Infections Treatment are expected to show stable ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs